Long-term survival of participants in the prostate cancer prevention trial.

Publication Type:

Journal Article


The New England journal of medicine, Volume 369, Issue 7, p.603-10 (2013)


2013, 5-alpha Reductase Inhibitors, Finasteride, Follow-Up Studies, Humans, Incidence, Kaplan-Meier Estimate, Male, Neoplasm Grading, Prostatic Neoplasms, Public Health Sciences Division, RISK, September 2013, Survival Rate


In the Prostate Cancer Prevention Trial (PCPT), finasteride significantly reduced the risk of prostate cancer but was associated with an increased risk of high-grade disease. With up to 18 years of follow-up, we analyzed rates of survival among all study participants and among those with prostate cancer.